clinical trial · NCT02559778
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
Giselle Sholler·phase2·recruiting·n = 500
NeuroblastomaCeritinibdasatinibsorafenibvorinostatDFMO
brief summary
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
started
Sep 1, 2015
primary completion
Sep 1, 2030
completion
Sep 1, 2035
last updated
Feb 20, 2026
official title
A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol